NCT07770568Not yet recruiting
Detection of Specific Metabolic Signatures by Nuclear Magnetic Resonance or Metabolomic NMR in Correlation With Markers of Inflammation or Immune Activation and the Risk of Developing Neurocognitive Disorders - Longitudinal Retrospective Study Nested in the ANRS12225 PEDIACAM III Cohort
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The ANRS12225 PEDIACAM III cohort involves a cohort of young adolescents living with HIV placed early (median: 4 months) on antiretroviral therapy (ART) and living without HIV monitored in Cameroon. This cohort follows the evolution of the psychomotor development of children living with HIV by mother-to-child transmission under antiretroviral treatment (ART) since birth as part of the cohort between 2016-2017 in children aged 4-9 years (ANRS12322 -PEDIACAMDEV) using the KABC II (Kaufman Assessment Battery for Children II). Despite early ART, children with HIV had significantly lower cognitive scores than uninfected children. Multiple neurodevelopmental studies have shown that intrauterine infection or even low- noise inflammation could impact the development of a child's brain allowing cognitive impairment to appear later in life. Other studies have also shown that metabolic defects could be the cause of chronic inflammation and immune activation. Admittedly, many studies have been carried out in cohorts of HIV-positive adults as well as HIV-positive children on neurological disorders. But very few have made the link between metabolism, inflammation, immune activation and neurocognitive disorders in infants and children in countries with limited resources. The ANRS12225 PEDIACAM III cohort offers the unique opportunity in Africa to carry out a study in a population of children living with HIV matched with a population of children living without HIV born to HIV + mothers and children living without HIV born to HIV-infected mothers in follow-up longitudinal. To explore this area, this pilot project will make it possible to assess the relevance of a cutting-edge, highthroughput technique, metabolomic NMR (Nuclear magnetic resonance), to quantify metabolites and lipoproteins in plasma and study their predictive value for the appearance of Neurodevelopmental disorders in children of different groups of the ANRS12225 PEDIACAM III cohort. It is intended to be completed within a short period (18 months) in order to be continued by more ambitious projects
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 128 (estimated)
- First submitted
- 13 Aug 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- ANRS, Emerging Infectious Diseases
- Diseases
- HIV
- NCT number
- NCT07770568
What you commit to
- Study type: Observational
- Planned participants: 128
- From 1 Aug 2026 to the primary completion date, 31 Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Any infected or uninfected child in the ANRS 12225 Pediacam III cohort who participated in the ANRS 12322 - PediacamDev study on the evaluation of neurocognitive development and who had the results of the KABC II test (IPM and INV).
- Children still followed in the ANRS cohort - Pediacam III having participated in the ANRS 12322 study - PediacamDev having results of the KABC II test (IPM and INV) and having plasma samples and never thawed in sufficient quantity (500 microliter) ; at different times of longitudinal follow-up: at 6 (±1.5) months and 12 (± 3) months, and at 108 (± 6) months.
Age in the registry: 13 years to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.